ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on November 5, 2024. The filing primarily addresses significant changes in executive leadership and references the company's financial results for the third quarter ended September 30, 2024, which were announced via a press release on November 7, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Executive Departures
- Departure of CFO: Peter Garcia resigned as Chief Financial Officer effective November 8, 2024, citing personal reasons. The resignation is not related to any disagreement with the company regarding operations, policies, or practices.
- Appointment of Interim CFO: On November 7, 2024, the Board appointed Shelly Pinto, Senior Vice President of Finance and Chief Accounting Officer, as the interim Chief Financial Officer effective upon Mr. Garcia's departure.
- Compensation: Ms. Pinto continues under her existing compensation arrangement with no new arrangements or understandings disclosed.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, or management commentary regarding future financial performance. The company has commenced a search for a permanent Chief Financial Officer. No specific risks or contingencies are detailed in this report beyond the standard transition of executive leadership.
Key Facts for Investor Verification
- Verify the specific Q3 2024 financial results (revenue, cash position, and burn rate) in the press release dated November 7, 2024 (Exhibit 99.1).
- Monitor the timeline for the appointment of a permanent Chief Financial Officer to ensure continuity in financial reporting and strategy.
- Review the company's cash runway given the absence of revenue data in this filing and the typical capital-intensive nature of oncology development.